2632-14-6

Usage

Uses

Used in Pharmaceutical Industry:
2-bromo-4-ethylacetophenone is used as a key intermediate in the synthesis of pharmaceuticals for its ability to be readily transformed into a variety of medicinally relevant compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-bromo-4-ethylacetophenone serves as a precursor in the production of various agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals that enhance crop protection and yield.
Used in Dye Industry:
2-bromo-4-ethylacetophenone is utilized as a starting material in the synthesis of dyes, where its chemical properties enable the creation of a range of colorants used in different industries, including textiles and printing.
Used in Perfumery and Flavoring Industry:
2-bromo-4-ethylacetophenone is also used as a building block in the production of perfumes and flavoring agents, capitalizing on its potential to contribute to the creation of unique scents and tastes.
Used in Medicinal Chemistry and Drug Discovery Research:
2-bromo-4-ethylacetophenone has potential applications in medicinal chemistry and drug discovery research, where its reactivity in chemical transformations is harnessed to explore new therapeutic agents and improve existing ones.
It is important to handle 2-bromo-4-ethylacetophenone with care due to its potential hazards, such as flammability and toxicity, ensuring safety in its applications across various industries.

Upstream product

• 100-41-4 ethylbenzene 
• 598-21-0 2-Bromoacetyl bromide 
• 937-30-4 4-ethylacetophenone 
• 1345683-42-2 1-bromo-2-(4-ethylphenyl)acetylene 
• 40307-11-7 1-ethyl-4-ethynylbenzene 
• 619-64-7 p-ethylbenzoic acid 
• 186581-53-3 diazomethane 
• 16331-45-6 p-ethylbenzoyl chloride 

Downstream Products

• 6097-24-1 1-(4-ethylphenyl)-2-thiocyanatoethan-1-one 
• 78394-77-1 1-[2-(4-Ethyl-phenyl)-2-oxo-ethyl]-2,5-dimethyl-4-phenyl-pyridinium; bromide 
• 78394-92-0 7-(4-Ethyl-benzyl)-2-(4-ethyl-phenyl)-6-methyl-indolizine 
• 142818-16-4 2-[Benzyl-(2-iodo-benzyl)-amino]-1-(4-ethyl-phenyl)-ethanone 
• 140420-15-1 1-(4-Ethyl-phenyl)-2-[(2-iodo-benzyl)-methyl-amino]-ethanone 
• 96885-28-8 p-Ethylbenzoylmethyl-8-bromotheophyllin 
• 887908-69-2 benzofuran-2-yl-(4-ethyl-phenyl)-methanol 
• 1002234-62-9 C₁₉H₁₇NO₃ 
• 1228793-52-9 2-(2-amino-5-(4-ethylphenyl)-3-furanyl)-1,3-dimethyl-1H-benzimidazolium bromide 
• 1448807-21-3 C₁₇H₁₈N₄O₂ 
• 1160554-10-8 C₁₄H₂₁NO₂ 

Relevant academic research and scientific papers

Novel Aryl-Substituted Pyrimidones as Inhibitors of 3-Mercaptopyruvate Sulfurtransferase with Antiproliferative Efficacy in Colon Cancer

The enzyme 3-mercaptopyruvate sulfurtransferase (3-MST) is one of the more recently identified mammalian sources of H2S. A recent study identified several novel 3-MST inhibitors with micromolar potency. Among those, (2-[(4-hydroxy-6-methylpyrimidin-2-yl)sulfanyl]-1-(naphthalen-1-yl)ethan-1-one) or HMPSNE was found to be the most potent and selective. We now took the central core of this compound and modified the pyrimidone and the arylketone sides independently. A 63-compound library was synthesized; compounds were tested for H2S generation from recombinant 3-MST in vitro. Active compounds were subsequently tested to elucidate their potency and selectivity. Computer modeling studies have delineated some of the key structural features necessary for binding to the 3-MST's active site. Six novel 3-MST inhibitors were tested in cell-based assays: they exerted inhibitory effects in murine MC38 and CT26 colon cancer cell proliferation; the antiproliferative effect of the compound with the highest potency and best cell-based activity (1b) was also confirmed on the growth of MC38 tumors in mice.

Reactivity of substrates with multiple competitive reactive sites toward NBS under neat reaction conditions promoted by visible light

Regioselectivity of visible-light-induced transformations of a range of (hetero)aryl alkyl-substituted ketones bearing several competitive reactive sites (α-carbonyl, benzyl and aromatic ring) with N-bromosuccinimide (NBS) was studied under solvent-free reaction conditions (SFRC) and in the absence of inert-gas atmosphere, radical initiators and catalysts. An 8-W energy-saving household lamp was used for irradiation. Heterogeneous reaction conditions were dealt with throughout the study. All substrates were mono- or dibrominated at the α-carbonyl position, and additionally, some benzylic or aromatic bromination was observed in substrates with benzylic carbon atoms or electron-donating methoxy groups, respectively. Surprisingly, ipso-substitution of the acyl group with a bromine atom took place with (4-methoxynaphthyl) alkyl ketones. While the addition of the radical scavenger TEMPO (2,2,6,6-tetramethylpiperidin-1-yloxy) decreased the extent of α- and ring bromination, it completely suppressed the benzylic bromination and α,α-dibromination with NBS under SFRC.

Synthesis and Structure-Activity Relationship of Dual-Stage Antimalarial Pyrazolo[3,4- b]pyridines

Malaria remains one of the most deadly infectious diseases, causing hundreds of thousands of deaths each year, primarily in young children and pregnant mothers. Here, we report the discovery and derivatization of a series of pyrazolo[3,4-b]pyridines targeting Plasmodium falciparum, the deadliest species of the malaria parasite. Hit compounds in this series display sub-micromolar in vitro activity against the intraerythrocytic stage of the parasite as well as little to no toxicity against the human fibroblast BJ and liver HepG2 cell lines. In addition, our hit compounds show good activity against the liver stage of the parasite but little activity against the gametocyte stage. Parasitological profiles, including rate of killing, docking, and molecular dynamics studies, suggest that our compounds may target the Qo binding site of cytochrome bc1.

Discovery of novel potent GPR40 agonists containing imidazo[1,2-a]pyridine core as antidiabetic agents

Free fatty acid receptor 1 (FFA1 or GPR40) has been studied for many years as a target for the treatment of type 2 diabetes mellitus. In order to increase potency and reduce hepatotoxicity, a series of novel compounds containing imidazo[1,2-a]pyridine sca

A focused structure-activity relationship study of psoralen-based immunoproteasome inhibitors

The immunoproteasome is a multicatalytic protease that is predominantly expressed in cells of hematopoietic origin. Its elevated expression has been associated with autoimmune diseases, various types of cancer, and inflammatory diseases. The development of immunoproteasome-selective inhibitors with non-peptidic scaffolds remains a challenging task. Here, we describe a focused series of psoralen-based inhibitors of the β5i subunit of the immunoproteasome with different substituents placed at position 4′. The most promising compound was further evaluated through changes at position 3 of the psoralen ring. Despite a small decrease in the inhibitory potency in comparison with the parent compound, we were able to improve the selectivity against other subunits of both the immunoproteasome and the constitutive proteasome. The most potent compounds discriminated between both proteasome types in cell lysates and also showed a decrease in cytokine secretion in peripheral blood mononuclear cells.

Microwave synthesis of 1-aryl-1H-pyrazole-5-amines

A microwave-mediated synthesis of 1H-pyrazole-5-amines utilizing 1 M HCl at 150 °C was developed in order to provide products in a matter of minutes with minimal purification. Most reactions are complete in only 10 min and can be isolated via a simple filtration without the need for further purification by column chromatography or recrystallization. This method tolerates a range of functional groups and can be performed on milligram to gram scales.

Synthesis and Evaluation of 2-Azetidinone and 1H-Pyrrole-2,5-dione Derivatives as Cholesterol Absorption Inhibitors for Reducing Inflammation Response and Oxidative Stress

Excess lipid accumulation can initiate the development and progression of atherosclerotic lesions, thus eventually leading to cardiovascular disease. Lipid-lowering medication therapy is one of the cornerstones of cardiovascular disease therapy. On the basis of the cholesterol absorption inhibitor ezetimibe, we successfully synthesized seven 2-azetidinone derivatives and eighteen 1H-pyrrole-2,5-dione derivatives. Most of the new compounds significantly inhibited cholesterol uptake in vitro. In addition, one of the most active inhibitors, 3-(4-fluorophenyl)-1-[(3S)-3-hydroxy-3-(4-hydroxyphenyl)propyl]-4-(4-hydroxyphenyl)-1H-pyrrole-2,5-dione (14q), showed no cytotoxicity in L02 and HEK293T cell lines. Further evaluation indicated that 14q inhibited considerably the amount of TNF-α, ROS, MDA, and LDH in vitro. Therefore, 14q might be a novel cholesterol absorption inhibitor.

Identification of Anti-Mycobacterial Biofilm Agents Based on the 2-Aminoimidazole Scaffold

Tuberculosis (TB) remains a significant global health problem for which new therapeutic options are sorely needed. The ability of the causative agent, Mycobacterium tuberculosis, to reside within host macrophages and form biofilm-like communities contributes to the persistent and drug-tolerant nature of the disease. Compounds that can prevent or reverse the biofilm-like phenotype have the potential to serve alongside TB antibiotics to overcome this tolerance, and decrease treatment duration. Using Mycobacterium smegmatis as a surrogate organism, we report the identification of two new 2-aminoimidazole compounds that inhibit and disperse mycobacterial biofilms, work synergistically with isoniazid and rifampicin to eradicate preformed M. smegmatis biofilms in vitro, are nontoxic toward Galleria mellonella, and exhibit stability in mouse plasma.

AuIII-Catalyzed Formation of α-Halomethyl Ketones from Terminal Alkynes

A AuIII-catalyzed synthesis of α-halomethyl ketones from terminal alkynes was developed. This approach features excellent functional group compatibility and good yields for both aromatic and aliphatic terminal alkynes. The resulting α-halomethyl ketones were used to prepare heterocyclic indolizine structures. The plausible mechanism of the one-pot reaction is proposed.